Pacific Biosciences of California (PACB) said Thursday it has appointed Chris Smith, chief executive of NeoGenomics (NEO), to the board of directors, effective immediately.
Smith has extensive experience in the life sciences and healthcare industries and led growth and innovation at NeoGenomics in precision medicine, Pacific Biosciences said.
The company said David Meline is resigning from its board, effective immediately, after contributing to the company's strategy since 2023.
Shares of Pacific Biosciences were up 1.9% and NeoGenomics rose 2.8% in recent trading.
Price: 1.59, Change: +0.03, Percent Change: +1.92
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。